Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Transfusion. 2010 Nov 23;51(5):921–928. doi: 10.1111/j.1537-2995.2010.02948.x

Table 2.

Steroid medications in platelet and granulocyte donors.

Route of administration Exposure level* Platelet donors (n=100) Granulocyte donors (n=100) p-value
Skin None 83% 79% 0.69
Moderate 12% 16%
High 5% 5%
Inhaled None 92% 91% 1.00
Moderate 7% 7%
High 1% 2%
Oral None 99% 100% 1.00
Moderate 1% 0%
Injected None 100% 100% .
Nasal None 77% 75% 0.68
Moderate 16% 20%
High 7% 5%
Ocular None 97% 94% 0.50
Yes 3% 6%
Overall exposure to steroids None 61% 54% 0.62
Moderate 24% 29%
High 15% 17%
*

Derivation of risk level from steroid medication history. For skin, inhaled, oral, injected, and nasal, the risk level was based on the approximate total duration of steroid medication use.

Exact likelihood ratio chi-squared test